Esteve Pharmaceuticals, S.A.
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Laboratorios Del DR. Esteve S.A. (to 2018)
17
Ending by 2030
Aug 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 1 to 24, 2027 · next Mar 1
- 1 fee due Apr 20, 2027The maintenance fee for Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof (US 9,161,902) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 2 fees due May 10, 2027
- 1 fee due Aug 4, 2027The maintenance fee for Co-crystals of tramadol and coxibs (US 10,548,909) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 2 fees due Sep 8 to 17, 2027 · next Sep 8
- 1 fee due Oct 14, 2027The maintenance fee for Adenoassociated virus vectors for the treatment of mucopolysaccharidoses (US 10,617,771) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,067,427 | Pharmaceutical Compositions Comprising ZD6474 In force · High confidence | In force | High confidence | |
| US 9,393,220 | Co-crystals of tramadol and NSAIDs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,513,259 | Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,263,581 | Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,314,083 | Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,180,090 | Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,598,152 | Co-crystals of tramadol and coxibs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,012,440 | Co-Crystals of Tramadol and Coxibs In force · Low confidence | In force | Low confidence | |
| US 10,238,668 | Co-Crystals of Tramadol and Coxibs In force · Medium confidence | In force | Medium confidence | |
| US 10,245,276 | Co-Crystals of Tramadol and Coxibs In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 35: 8 patents in force now held by others · 43 lapsed for an unpaid fee · 3 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 2 abandoned · 16 no status recorded